Back to Journals » International Journal of Nanomedicine » Volume 8 » Issue 1

Cancer stem cell theory: therapeutic implications for nanomedicine

Authors Wang K, Wu X, Wang J, Huang J

Received 28 September 2012

Accepted for publication 28 December 2012

Published 28 February 2013 Volume 2013:8(1) Pages 899—908

DOI https://doi.org/10.2147/IJN.S38641

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4



Ke Wang,1 Xianguo Wu,2 Jianwei Wang,3 Jian Huang1,3

1Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education; Provincial Key Laboratory of Molecular Biology in Medical Sciences), 2Department of Clinical Laboratory, 3Department of Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China

Abstract: Evidence continues to accumulate showing that tumors contain a minority population of cells responsible for tumor initiation, growth, and recurrence. These are termed "cancer stem cells" (CSCs). Functional assays have identified the self-renewal and tumor-initiation capabilities of CSCs. Moreover, recent studies have revealed that these CSCs is responsible for chemotherapy resistance within a tumor. Several mechanisms of chemoresistance have been proposed, including increased Wnt/β-catenin and Notch signaling, as well as high expression levels of adenosine triphosphate-binding cassette transporters, an active DNA repair capacity, and slow rate of self-renewal. Nanoscale drug-delivery systems, which transport therapeutically active molecules, prolong circulation, and improve biodistribution in the body, may allow more effective and specific therapies to address the challenges posed by CSCs. In particular, some nanovehicles are being exploited for selective drug delivery to CSCs and show promising results. In this review, we highlight the mechanisms of drug resistance and the novel strategies using nanoscale drugs to eliminate CSCs.

Keywords: drug resistance, drug delivery, chemoresistance, Wnt/β-catenin signaling, Notch signaling

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.